person · Reporting owner

POTTER MYRTLE S

Disclosed activity across 12 companies

Tapewire entity: 13295
SEC CIK: 0001214130

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMAZON COM INCAMZN · Entity 1956	Director	April 12, 2009	April 13, 2009
Arbutus Biopharma CorpABUS · Entity 4953	Director	August 17, 2019	August 20, 2019
Axsome Therapeutics, Inc.AXSM · Entity 2469	Director	June 07, 2019	June 10, 2019
Guardant Health, Inc.GH · Entity 3238	Director	June 22, 2026	June 23, 2026
INSMED IncINSM · Entity 3174	Director	May 15, 2018	May 17, 2018
Immunovant, Inc.IMVT · Entity 3632	Director	December 18, 2019	December 20, 2019
NEW RITE AID, LLCRAD · Entity 87704	Director	October 03, 2017	October 05, 2017
Sio Gene Therapies Inc.AXGT · Entity 130622	Director	April 15, 2019	April 18, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMAZON COM INC

Report date April 12, 2009 · Filed April 13, 2009

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.01 per shareSEC Table I · non-derivative	Direct	6,500	Reported balance After 2009-04-12 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2009-04-12 · Exercise / conversion · Acquired 2,500 · Balance 6,500 F1: By trust.
Common Stock, par value $.01 per shareSEC Table I · non-derivative	Direct	2,883	Reported balance Holding disclosure · report date 2009-04-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,883
Restricted Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2009-04-12	Direct	0	Reported balance After 2009-04-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-04-12 · Exercise / conversion · Disposed 2,500 · Balance 0 F2: Converts into Common Stock on a one-for-one basis. F3: Subject to the reporting person's continued service as a director of the issuer, this award vested and converted into shares of common stock of the issuer at the rate of 60% on April 12, 2007, an additional 20% on April 12, 2008 and an additional 20% on April 12, 2009.

Filing footnotes · ownership attribution and instrument terms

F1: By trust.

F2: Converts into Common Stock on a one-for-one basis.

F3: Subject to the reporting person's continued service as a director of the issuer, this award vested and converted into shares of common stock of the issuer at the rate of 60% on April 12, 2007, an additional 20% on April 12, 2008 and an additional 20% on April 12, 2009.

Arbutus Biopharma Corp

Report date August 17, 2019 · Filed August 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2029-08-17	Direct	22,000	Reported balance After 2019-08-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-08-17 · Grant · Acquired 22,000 · Balance 22,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant.

Axsome Therapeutics, Inc.

Report date June 07, 2019 · Filed June 10, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.03 · Expires 2029-06-07	Direct	13,000	Reported balance After 2019-06-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-07 · Grant · Acquired 13,000 · Balance 13,000 F1: The option vests in full on the one-year anniversary of the date of grant, June 7, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the one-year anniversary of the date of grant, June 7, 2020.

Guardant Health, Inc.

Report date June 22, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,971	Reported balance After 2026-06-22 transaction · row 1 1 source row Row 1 · 2026-06-22 · Sale · Disposed 1,556 · Balance 20,971

INSMED Inc

Report date May 15, 2018 · Filed May 17, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,510	Reported balance After 2018-05-15 transaction · row 1 1 source row Row 1 · 2018-05-15 · Grant · Acquired 6,066 · Balance 25,510 F1: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date.

F2: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock.

Immunovant, Inc.

Report date December 18, 2019 · Filed December 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.86 · Expires 2029-06-19	Direct	137,617	Reported balance After 2019-12-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-12-18 · Grant · Acquired 137,617 · Balance 137,617 F2: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd. (the "Business Combination Transaction"), the option to purchase 281,387 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.86 · Expires 2029-07-28	Direct	893	Reported balance After 2019-12-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-18 · Grant · Acquired 893 · Balance 893 F3: In connection with the Business Combination Transaction, the option to purchase 1,825 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-10-20	Direct	11,488	Reported balance After 2019-12-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-18 · Grant · Acquired 11,488 · Balance 11,488 F4: In connection with the Business Combination Transaction, the option to purchase 23,489 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-11-19	Direct	3,765	Reported balance After 2019-12-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-18 · Grant · Acquired 3,765 · Balance 3,765 F5: In connection with the Business Combination Transaction, the option to purchase 7,698 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer. F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.

F2: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd. (the "Business Combination Transaction"), the option to purchase 281,387 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).

F3: In connection with the Business Combination Transaction, the option to purchase 1,825 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

F4: In connection with the Business Combination Transaction, the option to purchase 23,489 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

F5: In connection with the Business Combination Transaction, the option to purchase 7,698 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer.

NEW RITE AID, LLC

Report date October 03, 2017 · Filed October 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	78,790	Reported balance After 2017-10-03 transaction · row 1 1 source row Row 1 · 2017-10-03 · Sale · Disposed 28,189 · Balance 78,790 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.09 to $2.095, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.09 to $2.095, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Sio Gene Therapies Inc.

Report date April 15, 2019 · Filed April 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-04-14	Direct	255,000	Reported balance After 2019-04-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-04-15 · Grant · Acquired 255,000 · Balance 255,000 F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Everyday Health, Inc.

Report date December 03, 2016 · Filed December 06, 2016

Section 16 reporting ended · disclosed 2016-12-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2016-12-05 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2016-12-03 · Other · Disposed 2,008 · Balance 16,375 F1: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company (the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). Row 2 · 2016-12-05 · Disposition to issuer · Disposed 16,375 · Balance 0 F2: Pursuant to the terms of the award, the vesting of restricted stock units for an aggregate of 16,375 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35	Direct	Reported balance After 2016-12-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-12-05 · Disposition to issuer · Disposed 23,333 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.87	Direct	Reported balance After 2016-12-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-12-05 · Disposition to issuer · Disposed 23,333 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.68	Direct	Reported balance After 2016-12-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-12-05 · Disposition to issuer · Disposed 27,978 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company (the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").

F2: Pursuant to the terms of the award, the vesting of restricted stock units for an aggregate of 16,375 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding).

F3: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).

Ginkgo Bioworks Holdings, Inc.

Report date June 11, 2025 · Filed June 13, 2025

Section 16 reporting ended · disclosed 2025-06-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	10,822	Reported balance After 2025-06-11 transaction · row 1 1 source row Row 1 · 2025-06-11 · Exercise / conversion · Acquired 10,822 · Balance 10,822 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2025-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-11 · Exercise / conversion · Disposed 10,822 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 13, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 13, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.

Myovant Sciences Ltd.

Report date March 10, 2023 · Filed March 10, 2023

Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-03-10 transaction · row 1 1 source row Row 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.17 · Expires 2028-09-19	Direct	Reported balance After 2023-03-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-10 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22	Direct	Reported balance After 2023-03-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-10 · Disposition to issuer · Disposed 58,608 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14	Direct	Reported balance After 2023-03-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04	Direct	Reported balance After 2023-03-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.

F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").

F4: These options are fully vested.

F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

Urovant Sciences Ltd.

Report date March 29, 2021 · Filed March 31, 2021

Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-03-29 · Disposition to issuer · Disposed 12,480 · Balance 0 F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-03-29 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2028-11-21	Direct	Reported balance After 2021-03-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-29 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2029-07-09	Direct	Reported balance After 2021-03-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-29 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2030-07-21	Direct	Reported balance After 2021-03-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-03-29 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 13, 2024 Filed Jun 14, 2024 20:18 UTC	Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530	GrantRestricted Stock Units · Derivative	432,900	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-24-018703 · form4.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,900 Underlying: Class A Common Stock · 432,900 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: The vesting date of the RSUs and additional initial options, and in the case of the additional initial options, the exercise date, will be the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. F4 · derivative.expiration_date: The vesting date of the RSUs and additional initial options, and in the case of the additional initial options, the exercise date, will be the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:18 UTC	Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530	GrantStock Option · Derivative	571,428	$0.00 Strike: $0.46	$0.00	Disclosure SEC source: 0001127602-24-018703 · form4.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 571,428 Underlying: Class A Common Stock · 571,428 shares Expires 2034-06-13 F3 · shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the additional initial option award as of the grant date is $200,000. F4 · derivative.exercise_date: The vesting date of the RSUs and additional initial options, and in the case of the additional initial options, the exercise date, will be the day immediately prior to the date of the next Annual Meeting of Shareholders of the Issuer occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. F3 · derivative.underlying_shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the additional initial option award as of the grant date is $200,000. Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:18 UTC	Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530	GrantStock Option · Derivative	1,111,111	$0.00 Strike: $0.46	$0.00	Disclosure SEC source: 0001127602-24-018703 · form4.xml · derivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,111,111 Underlying: Class A Common Stock · 1,111,111 shares Expires 2034-06-13 F1 · shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the initial option award as of the grant date is $400,000. F2 · derivative.exercise_date: The initial stock options shall vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, such that the initial stock options shall be fully vested on the third anniversary of the date of grant, subject to the Reporting Person continuing in service as a Non-Employee Director through such date. F1 · derivative.underlying_shares: In accordance with the Non-Employee Director Compensation Program of the Issuer, the Black-Scholes value of the initial option award as of the grant date is $400,000. Read SEC document
June 12, 2024 Filed Jun 14, 2024 00:58 UTC	Guardant Health, Inc. GH · Entity 3238	GrantRestricted Stock Units · Derivative	6,674	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-24-000140 · wk-form4_1718326701.xml · derivative · entry 4 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,674 Underlying: Common Stock · 6,674 shares Expires not disclosed F4 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 12, 2024 or the date of the next year annual stockholders meeting, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
June 12, 2024 Filed Jun 14, 2024 00:58 UTC	Guardant Health, Inc. GH · Entity 3238	GrantStock Option (Right to Buy) · Derivative	10,703	$0.00 Strike: $31.84	$0.00	Disclosure SEC source: 0001576280-24-000140 · wk-form4_1718326701.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,703 Underlying: Common Stock · 10,703 shares Expires 2034-06-12 F3 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 12, 2024 or the date of the next year annual stockholders meeting, whichever is earlier. Read SEC document
June 12, 2024 Filed Jun 14, 2024 00:58 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRestricted Stock Units · Derivative	5,592	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-24-000140 · wk-form4_1718326701.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
June 12, 2024 Filed Jun 14, 2024 00:58 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCommon Stock	5,592	$0.00	$0.00	Disclosure SEC source: 0001576280-24-000140 · wk-form4_1718326701.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 15, 2024 Filed May 16, 2024 22:15 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRestricted Stock Units · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-24-000117 · wk-form4_1715897719.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,163 Underlying: Common Stock · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
May 15, 2024 Filed May 16, 2024 22:15 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCommon Stock	69	$0.00	$0.00	Disclosure SEC source: 0001576280-24-000117 · wk-form4_1715897719.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 15, 2024 Filed Apr 16, 2024 22:33 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRestricted Stock Units · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-24-000090 · wk-form4_1713306828.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,232 Underlying: Common Stock · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
April 15, 2024 Filed Apr 16, 2024 22:33 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCommon Stock	68	$0.00	$0.00	Disclosure SEC source: 0001576280-24-000090 · wk-form4_1713306828.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2024 Filed Mar 18, 2024 22:14 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRestricted Stock Units · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-24-000061 · wk-form4_1710800051.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
March 15, 2024 Filed Mar 18, 2024 22:14 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCommon Stock	68	$0.00	$0.00	Disclosure SEC source: 0001576280-24-000061 · wk-form4_1710800051.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2024 Filed Feb 17, 2024 00:10 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRestricted Stock Units · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-24-000034 · wk-form4_1708128591.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,368 Underlying: Common Stock · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
February 15, 2024 Filed Feb 17, 2024 00:10 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCommon Stock	69	$0.00	$0.00	Disclosure SEC source: 0001576280-24-000034 · wk-form4_1708128591.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 15, 2024 Filed Jan 17, 2024 00:43 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-24-000022 · wk-form4_1705452210.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,437 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
January 15, 2024 Filed Jan 17, 2024 00:43 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	68	$0.00	$0.00	Disclosure SEC source: 0001576280-24-000022 · wk-form4_1705452210.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 15, 2023 Filed Dec 18, 2023 22:39 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000223 · wk-form4_1702939137.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,505 Underlying: COMMON STOCK · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
December 15, 2023 Filed Dec 18, 2023 22:39 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	69	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000223 · wk-form4_1702939137.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2023 Filed Nov 16, 2023 22:02 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000191 · wk-form4_1700172141.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,574 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
November 15, 2023 Filed Nov 16, 2023 22:02 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	68	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000191 · wk-form4_1700172141.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,240 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 15, 2023 Filed Oct 16, 2023 22:28 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000179 · wk-form4_1697495276.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,642 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
October 15, 2023 Filed Oct 16, 2023 22:28 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	68	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000179 · wk-form4_1697495276.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 15, 2023 Filed Sep 19, 2023 23:07 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000159 · wk-form4_1695164820.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,710 Underlying: COMMON STOCK · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
September 15, 2023 Filed Sep 19, 2023 23:07 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	69	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000159 · wk-form4_1695164820.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 15, 2023 Filed Aug 16, 2023 22:57 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000133 · wk-form4_1692226662.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,779 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
August 15, 2023 Filed Aug 16, 2023 22:57 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	68	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000133 · wk-form4_1692226662.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 15, 2023 Filed Jul 17, 2023 20:51 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000111 · wk-form4_1689627058.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,847 Underlying: COMMON STOCK · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
July 15, 2023 Filed Jul 17, 2023 20:51 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	69	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000111 · wk-form4_1689627058.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2023 Filed Jun 16, 2023 22:12 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000101 · wk-form4_1686953541.xml · derivative · entry 6 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,916 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
June 15, 2023 Filed Jun 16, 2023 22:12 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	68	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000101 · wk-form4_1686953541.xml · nonDerivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 14, 2023 Filed Jun 16, 2023 22:12 UTC	Guardant Health, Inc. GH · Entity 3238	GrantRESTRICTED STOCK UNITS · Derivative	5,592	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000101 · wk-form4_1686953541.xml · derivative · entry 5 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,592 Underlying: COMMON STOCK · 5,592 shares Expires not disclosed F4 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
June 14, 2023 Filed Jun 16, 2023 22:12 UTC	Guardant Health, Inc. GH · Entity 3238	GrantSTOCK OPTION (RIGHT TO BUY) · Derivative	8,803	$0.00 Strike: $38.01	$0.00	Disclosure SEC source: 0001576280-23-000101 · wk-form4_1686953541.xml · derivative · entry 4 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,803 Underlying: COMMON STOCK · 8,803 shares Expires 2033-06-14 F3 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier. Read SEC document
June 14, 2023 Filed Jun 16, 2023 22:12 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	5,531	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000101 · wk-form4_1686953541.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 5,531 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 15, 2022 or the date of the next year annual stockholders meeting whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
June 14, 2023 Filed Jun 16, 2023 22:12 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionCOMMON STOCK	5,531	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000101 · wk-form4_1686953541.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 15, 2023 Filed May 16, 2023 21:12 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000066 · wk-form4_1684271567.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,984 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
May 15, 2023 Filed May 16, 2023 21:12 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS	68	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000066 · wk-form4_1684271567.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 15, 2023 Filed Apr 17, 2023 21:41 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000051 · wf-form4_168176769394623.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,052 Underlying: COMMON STOCK · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
April 15, 2023 Filed Apr 17, 2023 21:41 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS	69	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000051 · wf-form4_168176769394623.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2023 Filed Mar 16, 2023 21:27 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000042 · wf-form4_167900203270409.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,121 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
March 15, 2023 Filed Mar 16, 2023 21:27 UTC	Guardant Health, Inc. GH · Entity 3238	GrantRESTRICTED STOCK UNITS	68	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000042 · wf-form4_167900203270409.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,162 Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:32 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	21,096	Not disclosed Strike: $22.71	Not disclosed	Disclosure SEC source: 0001209191-23-017723 · doc4.xml · derivative · entry 5 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,096 shares Expires 2031-11-04 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:32 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	21,603	Not disclosed Strike: $21.47	Not disclosed	Disclosure SEC source: 0001209191-23-017723 · doc4.xml · derivative · entry 4 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:32 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	58,608	Not disclosed Strike: $7.65	Not disclosed	Disclosure SEC source: 0001209191-23-017723 · doc4.xml · derivative · entry 3 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 58,608 shares Expires 2029-08-22 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:32 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerStock Options (Right to Buy) · Derivative	45,000	Not disclosed Strike: $26.17	Not disclosed	Disclosure SEC source: 0001209191-23-017723 · doc4.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,000 shares Expires 2028-09-19 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: These options are fully vested. Read SEC document
March 10, 2023 Filed Mar 10, 2023 14:32 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Disposition to issuerCommon Shares	3,673	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-017723 · doc4.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2 · shares: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3 · price: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). Read SEC document
February 15, 2023 Filed Feb 16, 2023 21:56 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	69	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000015 · wf-form4_167658455772932.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189 Underlying: COMMON STOCK · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
February 15, 2023 Filed Feb 16, 2023 21:56 UTC	Guardant Health, Inc. GH · Entity 3238	GrantRESTRICTED STOCK UNITS	69	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000015 · wf-form4_167658455772932.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,094 Read SEC document
January 15, 2023 Filed Jan 17, 2023 23:16 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS · Derivative	68	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001576280-23-000009 · wf-form4_167399736783300.xml · derivative · entry 2 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,258 Underlying: COMMON STOCK · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit vests as to 25% of the shares subject to such award on October 15, 2022, and as the remaining 75% of the shares subject to such award in substantially equal installments on each monthly anniversary of October 15, 2022, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document
January 15, 2023 Filed Jan 17, 2023 23:16 UTC	Guardant Health, Inc. GH · Entity 3238	Exercise / conversionRESTRICTED STOCK UNITS	68	$0.00	$0.00	Disclosure SEC source: 0001576280-23-000009 · wf-form4_167399736783300.xml · nonDerivative · entry 1 POTTER MYRTLE S · CIK 0001214130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.